TICKERNOMICS Sign up
Last Update: 2023-12-23 05:59:56
IOVANCE BIOTHERAPEUTICS INC. ( IOVA ) https://www.iovance.com
7.89USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
IOVA
28.92%
SPY
30.72%
-84.13%
IOVA
SPY
112.82%
-1.87%
IOVA
SPY
201.04%
-16.95%
IOVA
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1939.50
1846.84
7.15
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-4.55
2743.28
2.88
-12.63
0.00
-4.32
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-25236.89
-825.37
-25965.17
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
6.0128
-143.26
-72.61
0.52
Other Earnings and Cash Flow Stats:
IOVANCE BIOTHERAPEUTICS INC. ( IOVA ) Net Income TTM ($MM) is -418.37
IOVANCE BIOTHERAPEUTICS INC. ( IOVA ) Operating Income TTM ($MM) is -436.65
IOVANCE BIOTHERAPEUTICS INC. ( IOVA ) Owners' Earnings Annual ($MM) is 0.00
IOVANCE BIOTHERAPEUTICS INC. ( IOVA ) Current Price to Owners' Earnings ratio is 0.00
IOVANCE BIOTHERAPEUTICS INC. ( IOVA ) EBITDA TTM ($MM) is -422.78
IOVANCE BIOTHERAPEUTICS INC. ( IOVA ) EBITDA Margin is -25965.17%
Capital Allocation:
IOVANCE BIOTHERAPEUTICS INC. ( IOVA ) has paid 0.00 dividends per share and bought back -88.0 million shares in the past 12 months
IOVANCE BIOTHERAPEUTICS INC. ( IOVA ) has reduced its debt by 86.285 million USD in the last 12 months
Capital Structure:
IOVANCE BIOTHERAPEUTICS INC. ( IOVA ) Interest-bearing Debt ($MM) as of last quarter is 1
IOVANCE BIOTHERAPEUTICS INC. ( IOVA ) Annual Working Capital Investments ($MM) are -581
IOVANCE BIOTHERAPEUTICS INC. ( IOVA ) Book Value ($MM) as of last quarter is 674
IOVANCE BIOTHERAPEUTICS INC. ( IOVA ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
IOVANCE BIOTHERAPEUTICS INC. ( IOVA ) has 267 million in cash on hand as of last quarter
IOVANCE BIOTHERAPEUTICS INC. ( IOVA ) has 90 million of liabilities due within 12 months, and long term debt 1 as of last quarter
IOVANCE BIOTHERAPEUTICS INC. ( IOVA ) has 245 common shares outstanding as of last quarter
IOVANCE BIOTHERAPEUTICS INC. ( IOVA ) has 0 million USD of preferred stock value
Academic Scores:
IOVANCE BIOTHERAPEUTICS INC. ( IOVA ) Altman Z-Score is 2.10 as of last quarter
IOVANCE BIOTHERAPEUTICS INC. ( IOVA ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
IOVANCE BIOTHERAPEUTICS INC. ( IOVA ) largest shareholder is Goldman Sachs Group Inc owning 3763638 shares at 29.70 ($MM) value
Merrill A Mcpeak(an insider) Bought 10000 shares of IOVANCE BIOTHERAPEUTICS INC. ( IOVA ) for the amount of $55600.00 on 2023-09-18
0.33% of IOVANCE BIOTHERAPEUTICS INC. ( IOVA ) is held by insiders, and 91.41% is held by institutions
IOVANCE BIOTHERAPEUTICS INC. ( IOVA ) went public on 2010-10-15
Other IOVANCE BIOTHERAPEUTICS INC. ( IOVA ) financial metrics:
FCF:-244.91
Unlevered Free Cash Flow:0.00
EPS:-1.85
Operating Margin:-25236.89
Gross Profit Margin:-825.37
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-67.51
Beta:0.52
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About IOVANCE BIOTHERAPEUTICS INC. ( IOVA ) :
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. Its lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. The company also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. It has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.